Jun 34 minPRESS RELEASEMEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer
May 293 minANNOUNCEMENTSHighlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer
May 284 minANNOUNCEMENTSMEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer
Apr 183 minANNOUNCEMENTSBridging science to care: insights on translational studies and our presence at AACR Congress 2024
Apr 93 minPRESS RELEASEMEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting
Apr 43 minPRESS RELEASEThe Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer